SCHEMBL256372

SCHEMBL256372

Cn1cnc2cncnc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.46
FDPS P14324 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
YTHDC1 Q96MU7 1/20 0.40
LTA4H P09960 1/20 0.39
CYP1A2 P05177 10/20 0.38
CYP3A4 P08684 9/20 0.38
TSHR P16473 5/20 0.38
CLK4 Q9HAZ1 3/20 0.38
DYRK1A Q13627 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
ALDH1A1 P00352 6/20 0.36
CYP2C9 P11712 6/20 0.36
CYP2C19 P33261 4/20 0.36
HSD17B10 Q99714 4/20 0.36
USP2 O75604 3/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30341176 1.00 GRM5 (0.46) GRM5FDPSADORA2AADORA1YTHDC1
Anisole SCHEMBL28293679 0.82 CYP1A2 (0.48) GRM5LTA4HCYP1A2CYP3A4TSHR
Benzamide SCHEMBL27825323 0.79 GRM5 (0.51) GRM5FDPSLTA4HCYP1A2CYP3A4
SCHEMBL2120550 0.77 FDPS (0.45) FDPSLTA4HCYP1A2CYP3A4TSHR
SCHEMBL28340215 0.76 FDPS (0.44) FDPSLTA4HCYP1A2CYP3A4TSHR
SCHEMBL1398869 0.75 FDPS (0.41) FDPSLTA4HCYP1A2CYP3A4TSHR
SCHEMBL9121476 0.75 FDPS (0.41) FDPSLTA4HCYP1A2CYP3A4TSHR
SCHEMBL10163117 0.75 FDPS (0.51) FDPSADORA2AADORA1LTA4HCYP1A2
SCHEMBL31024294 0.75 FDPS (0.51) FDPSADORA2AADORA1LTA4HCYP1A2
SCHEMBL5633 0.74 FDPS (0.42) FDPSLTA4HCYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250283063-A1 NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF HUIDAGENE THERAPEUTICS CO., LTD. (CN) 2025-09-11 US claimed
EP-4514954-A1 NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) 2025-03-05 EP claimed
EP-4514953-A1 NOVEL CRISPR-CAS12F SYSTEMS AND USES THEREOF Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) 2025-03-05 EP claimed
CN-119421948-A Novel CRISPR-Cas12f system and application thereof 辉大(上海)生物科技有限公司 2025-02-11 CN claimed
CN-119331309-A Methyl purine ferulic acid aromatized water magnesite composite material and preparation method and application thereof 江西广源化工有限责任公司 2025-01-21 CN claimed
CN-118749029-A Novel CRISPR-Cas12i system and application thereof 辉大(上海)生物科技有限公司 2024-10-08 CN claimed
WO-2024094084-A1 ISCB POLYPEPTIDES AND USES THEREOF HUIDAGENE THERAPEUTICS CO., LTD. (CN) 2024-05-10 WO claimed
CN-117820252-A Preparation and detection methods of nitroreductase hemicyanine dye fluorescent probes and visual application of nitroreductase hemicyanine dye fluorescent probes in clinical bacterial identification 华北理工大学 2024-04-05 CN claimed
CN-114410836-B Kit and method for detecting human parvovirus B19 by integrating sample treatment, nucleic acid extraction and multiplex isothermal amplification 上海交通大学医学院附属仁济医院 2024-03-01 CN claimed
CN-117460822-A Novel CRISPR-Cas12i system and application thereof 辉大基因治疗(新加坡)私人有限公司 2024-01-26 CN claimed
US-5985926-A VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS CELL THERAPEUTICS, INC. (US) 1999-11-16 US claimed
CN-1172417-A Feed for fishes and shellfishes PROD DEV RES INST (JP) 1998-02-04 CN claimed
US-5641783-A ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS CELL THERAPEUTICS, INC. (US) 1997-06-24 US claimed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP claimed
CN-1031403-C Hydroxyalkylfuranyl derivatives JANSSEN PHARMACEUTICA NV (BE) 1996-03-27 CN claimed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP claimed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO claimed
WO-1995013808-A1 METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION CELL THERAPEUTICS, INC. (US) 1995-05-26 WO claimed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO claimed
WO-1994018192-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK & CO., INC. (US) 1994-08-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250283063-A1 NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF RBM12, PRR12, HM13 GRM5 4341/4885FDPS 1681/4885ADORA2A 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.